Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that new analyses of data were presented from its clinical program and pivotal IMPRESS (The Ivestigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that evaluated XIAFLEX®(collagenase clostridium histolyticum or CCH) for the treatment of Peyronie’s disease (PD). These data were presented at the American Urological Association (AUA) Meeting held in Orlando, Florida on May 16-21, 2014.Â
“XIAFLEX is the first and only FDA-approved treatment for Peyronie’s disease in men with a palpable plaque and a penile curvature deformity of 30 degrees or greater at the start of therapy,†said James Tursi, M.D., Chief Medical Officer of Auxilium. “We believe this may offer patients, their partners and their physicians an important treatment option for this devastating disease.â€
Highlights of the information presented include: